Capricorn Fund Managers Ltd Takes Position in Phibro Animal Health Corporation $PAHC

Capricorn Fund Managers Ltd acquired a new position in Phibro Animal Health Corporation (NASDAQ:PAHC) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 252,928 shares of the company’s stock, valued at approximately $10,233,000. Phibro Animal Health makes up 3.4% of Capricorn Fund Managers Ltd’s investment portfolio, making the stock its 10th largest position. Capricorn Fund Managers Ltd owned 0.62% of Phibro Animal Health at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of PAHC. Acadian Asset Management LLC increased its position in Phibro Animal Health by 0.5% in the first quarter. Acadian Asset Management LLC now owns 782,939 shares of the company’s stock worth $16,713,000 after buying an additional 4,144 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Phibro Animal Health by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 554,927 shares of the company’s stock valued at $14,175,000 after acquiring an additional 7,841 shares during the period. Millennium Management LLC increased its holdings in Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after acquiring an additional 154,281 shares in the last quarter. Ranger Investment Management L.P. raised its stake in Phibro Animal Health by 101.1% during the 2nd quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after acquiring an additional 179,975 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its stake in Phibro Animal Health by 43.2% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 275,066 shares of the company’s stock worth $7,025,000 after acquiring an additional 83,018 shares during the period. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PAHC. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 22nd. Finally, JPMorgan Chase & Co. raised their price target on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $31.40.

Phibro Animal Health Stock Performance

PAHC opened at $38.17 on Friday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.35 and a current ratio of 3.09. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of 22.99, a PEG ratio of 1.08 and a beta of 0.77. The company has a fifty day moving average of $41.44 and a 200 day moving average of $35.60. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.58 by $0.15. The business had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, sell-side analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.3%. The ex-dividend date was Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio (DPR) is currently 28.92%.

Insider Transactions at Phibro Animal Health

In other news, CEO Jack Bendheim sold 5,752 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36. Following the sale, the chief executive officer directly owned 39,200 shares of the company’s stock, valued at $1,604,456. This represents a 12.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 146,554 shares of company stock valued at $6,338,444. Insiders own 50.13% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.